Clinical Trials Logo

Clinical Trial Summary

This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03578822
Study type Interventional
Source Tasly Pharmaceuticals, Inc.
Contact Haiqing Song, M.D
Phone 13701390976
Email songhq@vip.sina.com
Status Not yet recruiting
Phase Phase 3
Start date July 2018
Completion date December 2020